Esketamine first received FDA approval in 2019, but with an important restriction: it could only be used in combination with an oral antidepressant. That requirement, built into the original label and ...
Morning Overview on MSN
Ultrasound-triggered nanoparticles create light in tissue for therapy
Delivering light to a tumor buried centimeters inside the body has always required threading a fiber-optic cable through ...
Briya, the health AI technology company redefining healthcare research, today announced its global data network has expanded to cover over 120 million patient records. By unifying this massive ...
A major step forward in neonatal care will be underway Tuesday as Memorial Health becomes one of only three hospitals in the ...
FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk ...
Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously ...
The Food and Drug Administration will announce on Monday that it has sent over 2,200 letters pressing drug manufacturers, ...
PRO-XTEN dual masking aims to keep the engager inactive in circulation, activate within tumor protease-rich microenvironments ...
Kailera is taking another step into the competitive obesity market by aiming to raise up to $528.5 million via a Nasdaq IPO, ...
Clinical Trials Arena on MSN
Preparation is key to understanding global trade compliance for trials
Matthew Leets, head of global trade compliance at Alkermes, discusses the complexities of shipping investigational products ...
An experimental drug designed to silence a gene strongly linked to Parkinson's disease has shown encouraging effects in a ...
Two Alzheimer's drugs were hailed as treatments that would transform care. Why are barely any UK patients getting them?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results